Get started
Author

Iciar García Carbonero

Observed names: I Garcia Carbonero, I. Carbonero, I. Garcia Carbonero, I. García Carbonero, I.G. Carbonero, Iciar Garcia Carbonero, Iciar García-Carbonero, Iciar Garcı́a Carbonero, Icíar García Carbonero
Observed institutions: Hospital Clínico San Carlos, Spanish National Cancer Research Centre, Hospital Virgen de la Salud, Complejo Hospitalario Universitario de Toledo, Hôpital Paul-Brousse, Hospital Universitario de Toledo
ORCID: 0000-0003-1044-701X
Observed ORCID: 0000-0003-1044-701X
OpenAlex ID: A5023560654
Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients
2002 · Jose I. Chacón, Manuela Mollejo, et al. · Blood · 202
PDF
Long-term prognostic and predictive factors in 107 stage II/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy
1997 · E Brain, C Garrino, et al. · British Journal of Cancer · 48
PDF
Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain
2002 · Trinidad Caldes, Javier Godino, et al. · International Journal of Cancer · 45
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
2015 · B. Pérez-Valderrama, J.A. Arranz Arija, et al. · Annals of Oncology · 40
Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
2000 · M. Martin, A. Lluch, et al. · Annals of Oncology · 32
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
2018 · Antoine Angelergues, Eleni Efstathiou, et al. · Clinical Genitourinary Cancer · 22
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
1997 · J L González-Larriba, I Garcia Carbonero, et al. · PubMed · 22
Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action
2012 · José Luís González Larriba, Enrique Espinosa, et al. · Cancer and Metastasis Reviews · 18
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
2025 · T. Powles, S.A. Hussain, et al. · Annals of Oncology · 17
PDF
Real-world data on the efficacy and safety of weekly oral vinorelbine in breast cancer patients previously treated with anthracycline or taxane-based regimens
2018 · I. Blancas, E. Aguirre, et al. · Clinical & Translational Oncology · 12
Baseline 18F-Fluorocholine PET/CT and bone scan in the outcome prediction of patients treated with radium 223 dichloride
2018 · A. M. García Vicente, B. González García, et al. · Clinical & Translational Oncology · 12
Paclitaxel plus vinorelbine in metastatic breast Ca patients with contraindications to receive anthracyclines.
1998 · M Martin, A Casado, et al. · PubMed · 7
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
2014 · Xavier García del Muro, Enrique Gallardo, et al. · Cancer Chemotherapy and Pharmacology · 5
Impact of treatment sequence in metastatic castration-resistant prostate cancer (mCRPC) on outcome in a prospective cohort study.
2019 · Rebeca Lozano, Elena Castro, et al. · Journal of Clinical Oncology · 4
Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database.
2017 · Nicolas Delanoy, Antoine Angelergues, et al. · Journal of Clinical Oncology · 3
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
2025 · Cristina Suárez, Òscar Reig Torras, et al. · Clinical Genitourinary Cancer · 2
Split-Dose Cisplatin Plus Atezolizumab for Patients With Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA)
2025 · Guillermo de Velasco, Iciar García-Carbonero, et al. · JCO oncology advances. · 1
Phase 2 study of perioperative sacituzumab govitecan in combination with zimberelimab and domvanalimab for patients with muscle invasive bladder cancer ineligible or who refuse cisplatin-based chemotherapy: The PRISMA-1 study.
2025 · Ignacio Duran, Miguel A. Climent Duran, et al. · Journal of Clinical Oncology · 1
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group
2022 · Xavier García-del-Muro, Ignacio Durán, et al. · Clinical Genitourinary Cancer · 1
How do patterns of progression influence treatment selection after chemohormonal therapy in patients with metastatic hormone sensitive prostate cancer?
2017 · Carlos Aguado De La Rosa, Iciar Garcia Carbonero, et al. · Journal of Clinical Oncology · 1
Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)
2026 · Ignacio Peláez Fernández, Verónica Blanco Lorenzo, et al. · Clinical & Translational Oncology
Comparison of cisplatin/gemcitabine or carboplatin/gemcitabine on efficacy, toxicity, and quality of life from the randomized DISCUS trial.
2026 · Syed A. Hussain, Iciar García Carbonero, et al. · Journal of Clinical Oncology
Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.
2026 · Guillermo de Velasco, Iciar García Carbonero, et al. · Journal of Clinical Oncology
SOGUG-Vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.
2024 · Guillermo de Velasco, Iciar García Carbonero, et al. · Journal of Clinical Oncology
SOGUG-vexillum: Phase II non-randomized clinical trial of nivolumab/ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer.
2023 · Guillermo de Velasco, Carlos Alvarez-Fernandez, et al. · Journal of Clinical Oncology
Works count: 46
Citation count: 495
H-index: 11
I10-index: 11
Year
Topic
Type